Cormorant Asset Management, LP Apellis Pharmaceuticals, Inc. Transaction History

Cormorant Asset Management, LP

$1.43 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $12.5 Million - $16.3 Million	-225,000 Reduced 36.0%	400,000 $23.5 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $51.1 Million - $89.1 Million	-1,375,000 Reduced 68.75%	625,000 $37.4 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $16.3 Million - $61.6 Million	690,000 Added 52.67%	2,000,000 $76.1 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $3.83 Million - $4.67 Million	-50,000 Reduced 3.68%	1,310,000 $119 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $10.1 Million - $14.5 Million	-216,872 Reduced 13.75%	1,360,000 $89.7 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $4.28 Million - $6.04 Million	98,872 Added 6.69%	1,576,872 $81.5 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $23.6 Million - $36.8 Million	528,000 Added 55.58%	1,478,000 $101 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $6.14 Million - $10.4 Million	-175,000 Reduced 15.56%	950,000 $43 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $17.7 Million - $27.1 Million	500,000 Added 80.0%	1,125,000 $57.2 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $9.22 Million - $14.7 Million	-300,000 Reduced 32.43%	625,000 $29.6 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $2.36 Million - $5.24 Million	75,000 Added 8.82%	925,000 $30.5 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $41.6 Million - $65.9 Million	-1,016,108 Reduced 54.45%	850,000 $53.7 Million
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $5.18 Million - $6.73 Million	-200,000 Reduced 9.68%	1,866,108 $56.3 Million
Q2 2020 Aug 14, 2020	SELL	$24.8 - $38.49 $4.96 Million - $7.7 Million	-200,000 Reduced 8.83%	2,066,108 $67.5 Million
Q1 2020 May 15, 2020	SELL	$17.91 - $44.33 $7.77 Million - $19.2 Million	-433,892 Reduced 16.07%	2,266,108 $60.7 Million
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $6.1 Million - $8.5 Million	-276,000 Reduced 9.27%	2,700,000 $82.7 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $238,298 - $318,324	9,892 Added 0.33%	2,976,000 $71.7 Million
Q2 2019 Aug 14, 2019	SELL	$18.0 - $25.34 $11.4 Million - $16.1 Million	-633,892 Reduced 17.61%	2,966,108 $75.2 Million
Q1 2019 May 15, 2019	SELL	$12.81 - $19.82 $11.6 Million - $17.9 Million	-902,498 Reduced 20.04%	3,600,000 $70.2 Million
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $3.79 Million - $6.17 Million	330,000 Added 7.91%	4,502,498 $59.4 Million
Q3 2018 Nov 14, 2018	SELL	$16.57 - $21.03 $2.32 Million - $2.94 Million	-140,000 Reduced 3.25%	4,172,498 $74.2 Million
Q2 2018 Aug 14, 2018	BUY	$19.63 - $30.0 $4.4 Million - $6.73 Million	224,269 Added 5.49%	4,312,498 $94.9 Million
Q1 2018 May 15, 2018	BUY	$14.01 - $26.02 $4.48 Million - $8.31 Million	319,472 Added 8.48%	4,088,229 $90.4 Million
Q4 2017 Feb 14, 2018	BUY	$12.71 - $21.7 $47.9 Million - $81.8 Million	3,768,757	3,768,757 $81.8 Million

Others Institutions Holding APLS

# of Institutions

310

Shares Held

113M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$466 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$356 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$333 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$294 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$174 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Account